Skip to main content
OpenTrials
Completed

NCT Number: NCT06403072

(GI-RADS) in Preoperative Evaluation of Adnexal Masses

prospective study was conducted and performed on 100 women with pelvic pain due to accidently discovered adnexal mass

Completed

Looking for future studies?

Notify Me

Key information

About this study

After institutional ethical committee approval () and informed consent from the patients, this prospective study was conducted and performed on 100 women with pelvic pain due to accidently discovered adnexal mass

All women were subjected to the following:

  • Detailed history taking: Personal history, Age, Obstetric history, past history and family history.
  • Physical examination: General examination, Pelvic examination and Abdominal examination.
  • Investigations: Routine labs; CBC, liver and kidney functions, FBS and 2HPP. Other labs; cancer antigen 125 (CA 125) as a tumor marker.
  • Trans vaginal ultrasound: TVUS Written informed consent for participation and publication was obtained from each patient after receiving information about the details of the study. Confidentiality of patient's records was assured and maintained throughout the study.

One hundred (100) patients' pelvises were examined by transvaginal ultrasound in lithotomy position using endo-vaginal transducer and/or transabdominal ultrasound in the supine position in transverse and longitudinal plane and evaluated by B-mode ultrasonography, color, and spectral Doppler. Two expert examiners with more than 10 years' experience in gynecological ultrasound, performed all examinations and data was stored between one and four representative images on the database.

After the examinations, a combination of morphological features, color and spectral Doppler features, and then the lesion was evaluated according to GI-RADS classification, and the suggested management protocol based on the risk of malignancy.

Finally, the referral to surgery and decision-making were consulted in accordance with a multidisciplinary team meeting (MDT). A definitive histopathological diagnosis was obtained as a gold standard test for all patients with GI-RADS 4 and 5 and some cases of GI-RADS 3 patients after laparoscopic or surgical removal of the masses.

A morphologic evaluation was performed according to the International Ovarian Tumor Analysis Group (IOTA) recommendations for the following parameters: wall thickness, septation, papillary projections, presence and echogenicity of solid areas, presence of mixed component, cystic component, and presence of ascites and intra-abdominal metastases (peritoneal deposits, liver metastasis, and malignant abdominal lymphadenopathy) was also recorded. Pattern recognition analysis was also used for ovarian masses.

Statistical analysis:

The collected data was coded, tabulated, and statistically analyzed using IBM SPSS statistics (Statistical Package for Social Sciences) software version 22.0, IBM Corp., Chicago, USA, 2013 and Microsoft Office Excel 2007.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Females complaining of pelvic pain due to adnexal mass

Exclusion criteria

  • Presence of Sure signs of malignancy

Treatment and study plan

The Gynecologic Imaging-Reporting and Data System (GI-RADS)

Diagnostic Test

The Gynecologic Imaging-Reporting and Data System (GI-RADS) using ultrasound

Primary outcomes

  1. The Gynecologic Imaging-Reporting and Data System (GI-RADS)

    Time frame: 1 month from admission to ultrasound investigation and operation and finally histopathology report

    is a reporting system that was created for reporting the findings in adnexal masses based on transvaginal ultrasonography.

Sponsors and collaborators

Lead sponsor

Beni-Suef University

Other

Registry information

Official study title

Diagnostic Performance of the Gynecologic Imaging-Reporting and Data System (GI-RADS) in Preoperative Evaluation of Adnexal Masses

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
May 7, 2024
Registry last updated
May 7, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.